Connect to other sites within the UBM Medica Network
Elotuzumab Effective, Safe for Relapsed, Refractory Myeloma
Adding elotuzumab to lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma appears to result in better efficacy and safety.
Lung Mass Found in 68-Year-Old Patient With Chest Pain
A 68-year-old man presents with a cough and chest pain. Chest imaging shows a lung mass in the right upper lobe. What is your diagnosis?
Alectinib Shows Response in Crizotinib-Refractory NSCLC
The ALK inhibitor alectinib was highly active and well-tolerated in patients with ALK-rearranged, crizotinib-refractory, advanced non–small-cell lung cancer.
Nintedanib Delays Progression of Advanced Ovarian Cancer
Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when adding nintedanib to carboplatin/paclitaxel.
November 2015 News Roundup
In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
FDA Approves Necitumumab (Portrazza) for Advanced Squamous NSCLC
The FDA has approved necitumumab (Portrazza) in combination with chemotherapy for the treatment of patients with metastatic squamous non-small-cell lung cancer.
NYC Program Diminishes Disparities, Sees Uptick in CRC Screening
A program implemented in New York City successfully increased colorectal cancer screening rates and diminished racial and ethnic disparities in screening.
Innovative GBM Trial Could Hasten Development of New Treatments
Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.
Frontline Nivolumab Approved for BRAF Wild-type Melanoma
Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.
Epacadostat/Pembrolizumab Combo Shows Activity in Advanced Melanoma
The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.
By clicking Accept, you agree to become a member of the UBM Medica Community.